Oral tofacitinib - a promising treatment in atopic dermatitis, alopecia areata and vitiligo

Tofacitinib citrate is a Janus Kinase (JAK) 1/3 inhibitor from a novel therapeutic class of medications used in the treatment of systemic inflammatory disorders such as rheumatoid arthritis.1 There is also emerging evidence for the treatment of chronic plaque psoriasis,2 ulcerative colitis3 and renal transplant rejection,4 however its use in other dermatological conditions has not been well explored.
We report the first known case of oral tofacitinib treatment in a patient presenting with alopecia areata, vitiligo and treatment refractory atopic dermatitis. To monitor clinical response, an EASI (Eczema Area and Severity Index) and VASI (Vitiligo Area Scoring Index) score was determined alongside sequential clinical photography at each review. A twelve month course of therapy demonstrated clinical response in all three conditions and highlights the potential of tofacitinib as a unique monotherapy and alternative therapeutic option.

Dr. Mi Vu